Research
Hormonal
SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT-2 inhibitors like empagliflozin or canagliflozin. These pills help your body remove excess sugar through urine, which has been shown to significantly protect your heart and kidneys. They are often used alongside metformin.
StrongSupportsHIGH confidence
For all atherosclerotic CVD, SGLT-2i resulted in an 11% decrease in the 3p-MACE... Canagliflozin reduced CV death by 13% and empagliflozin reduced CV death by 38%... Canagliflozin reduced the primary renal-specific composite ESKD, renal or CV death by 34% over a median follow-up of 2.62 years.
Why this rating
Based on large CVOTs (EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE).
Source
Technological and Therapeutic Approaches to Type 2 Diabetes Management
Rekha Krishnan et al. · International Journal of Health Sciences and Research · 2023
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →